Artemis Therapeutics Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Artemis Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Artemis Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable primary indicators, Artemis Therapeutics is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 1000.00 | |
| Total Cashflows From Investing Activities | -27.3 K |
Artemis |
Artemis Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Artemis Therapeutics on November 7, 2025 and sell it today you would earn a total of 100.00 from holding Artemis Therapeutics or generate -100.0% return on investment over 90 days. Artemis Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Artemis, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Artemis Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Artemis Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Artemis Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Artemis Therapeutics is not yet fully synchronised with the market data | |
| Artemis Therapeutics has some characteristics of a very speculative penny stock | |
| Artemis Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Artemis Therapeutics currently holds 362.15 K in liabilities with Debt to Equity (D/E) ratio of 0.51, which is about average as compared to similar companies. Artemis Therapeutics has a current ratio of 0.71, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Artemis Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Artemis Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Artemis Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Artemis to invest in growth at high rates of return. When we think about Artemis Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Artemis Therapeutics currently holds about 149.4 K in cash with (73 K) of positive cash flow from operations. | |
| Roughly 88.0% of Artemis Therapeutics shares are held by company insiders |
Artemis Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Artemis Pink Sheet often depends not only on the future outlook of the current and potential Artemis Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Artemis Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.2 M | |
| Cash And Short Term Investments | 1000.00 |
Artemis Therapeutics Fundamentals Growth
Artemis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Artemis Therapeutics, and Artemis Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Artemis Pink Sheet performance.
| Return On Asset | -15.31 | |||
| Operating Margin | (5.25) % | |||
| Current Valuation | 168.32 M | |||
| Shares Outstanding | 112.03 M | |||
| Price To Earning | (18.35) X | |||
| Price To Book | 50.52 X | |||
| Price To Sales | 861.55 X | |||
| EBITDA | 167 K | |||
| Cash And Equivalents | 149.4 K | |||
| Total Debt | 362.15 K | |||
| Debt To Equity | 0.51 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (73 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 7 K | |||
| Retained Earnings | (2.37 M) | |||
| Current Asset | 3.6 M | |||
| Current Liabilities | 1.28 M | |||
Things to note about Artemis Therapeutics performance evaluation
Checking the ongoing alerts about Artemis Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Artemis Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Artemis Therapeutics is not yet fully synchronised with the market data | |
| Artemis Therapeutics has some characteristics of a very speculative penny stock | |
| Artemis Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Artemis Therapeutics currently holds 362.15 K in liabilities with Debt to Equity (D/E) ratio of 0.51, which is about average as compared to similar companies. Artemis Therapeutics has a current ratio of 0.71, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Artemis Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Artemis Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Artemis Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Artemis to invest in growth at high rates of return. When we think about Artemis Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Artemis Therapeutics currently holds about 149.4 K in cash with (73 K) of positive cash flow from operations. | |
| Roughly 88.0% of Artemis Therapeutics shares are held by company insiders |
- Analyzing Artemis Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Artemis Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Artemis Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Artemis Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Artemis Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Artemis Therapeutics' pink sheet. These opinions can provide insight into Artemis Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Artemis Pink Sheet
If you are still planning to invest in Artemis Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Artemis Therapeutics' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |